Key result
Elevated serum asprosin linked to ~97% higher odds of CAD in COPD patients.
Why the study?
COPD is linked to systemic inflammatory activity and an increased burden of CAD, motivating an examination of serum asprosin, FABP4, and vaspin levels in COPD patients according to the presence or absence of CAD.
Are serum asprosin, FABP4, and vaspin levels independently associated with and discriminative for the presence of coronary artery disease in patients with COPD?
Cross-Sectional (n=120)
No
Are serum asprosin, FABP4, and vaspin levels independently associated with and discriminative for the presence of coronary artery disease in patients with COPD?
Answers are grounded in this paper and cite their sources.
Serum levels of the adipokines asprosin, FABP4, and vaspin are significantly elevated and independently associated with the presence of coronary artery disease in patients with COPD, after adjusting for age and LDL cholesterol.
OBJECTIVE: Chronic obstructive pulmonary disease (COPD) is linked to systemic inflammatory activity and an increased burden of cardiovascular comorbidity, particularly coronary artery disease (CAD). This study aimed to examine serum asprosin, fatty acid-binding protein 4 (FABP4), and vaspin levels in COPD patients according to the presence or absence of CAD. MATERIAL AND METHODS: This prospective cross-sectional study included 120 participants: COPD (n = 40), COPD with CAD (n = 40), and healthy controls (n = 40). Serum biomarker levels were compared among groups. Receiver operating characteristic analysis and multivariable logistic regression were used to assess discriminative performance and independent associations. RESULTS: Biomarker levels differed significantly among groups ( P < 0.001). Median asprosin levels were 8.32, 14.98, and 11.88 ng/mL; median FABP4 levels were 205.86, 708.63, and 416.18 ng/L; and median vaspin levels were 4.37, 6.17, and 5.50 ng/mL in the COPD, COPD+CAD, and control groups, respectively. Area under the curve values were 0.898 for asprosin, 0.891 for vaspin, and 0.860 for FABP4 (all P < 0.001). After adjustment for age and low-density lipoprotein (LDL) cholesterol, asprosin [odds ratio (OR) 1.965, 95% confidence interval (CI) 1.436–2.691], FABP4 (OR 1.014, 95% CI 1.007–1.021), and vaspin (OR 2.896, 95% CI 1.767–4.745) remained independently associated with CAD (all P < 0.001). CONCLUSION: Serum asprosin, FABP4, and vaspin levels were elevated in COPD patients with CAD, and showed discriminative ability in this cohort, with each biomarker remaining associated with CAD after adjustment for age and LDL cholesterol. These findings require confirmation in larger prospective cohorts.
No takes yet. Share an insight, caveat, or question.
Aksakal et al. (2026) conducted a cross-sectional in Chronic obstructive pulmonary disease (COPD) with or without coronary artery disease (CAD) (n=120). Serum asprosin, FABP4, and vaspin levels (primary model: serum asprosin) vs. COPD patients without CAD (and healthy controls) was evaluated on Presence of coronary artery disease (CAD) in patients with COPD (associated with serum asprosin in multivariable analysis adjusted for age and LDL cholesterol) (OR 1.965, 95% CI 1.436-2.691, p=<0.001). Elevated serum asprosin, FABP4, and vaspin were independently associated with coronary artery disease in patients with COPD.
Synapse has enriched 10 related papers. Consider them for comparative context: